THE RESULTS OF THE USE OF 5-AMINOSALICYLIC ACID AS AN ANTI-RELAPSE AND MAINTENANCE THERAPY ULCERATIVE COLITIS MODERATE SEVERITY IN CLINICAL PRACTICE

by O. V. Knyazev, A. V. Kagramanova
Published 2018-01-01

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis

by O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya
Published 2021-05-01

Pharmacological and clinical feature of rebamipide: new therapeutic targets

by M. Yu. Zvyaglova, O. V. Knyazev, A. I. Parfenov
Published 2020-02-01

Systemic manifestations of inflammatory bowel diseases

by A. I. Parfenov, A. V. Kagramanova, O. V. Knyazev
Published 2020-02-01

Psoriasis and inflammatory bowel diseases: pathogenetic pathways and the choice of biologic therapy (a literature review)

by L. S. Kruglova, A. N. Lvov, A. V. Kagramanova, O. V. Knyazev
Published 2019-12-01

The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice

by O. V. Knyazev, A. V. Kagramanova, A. A. Lishchinskaya, A. I. Parfenov
Published 2019-10-01

Personalized medicine in the treatment of inflammatory bowel diseases

by A I Parfenov, O V Knyazev, A V Kagramanova, N A Fadeeva
Published 2018-02-01

Use of mesenchymal stem cells in the combination therapy of ulcerative colitis

by O V Knyazev, A I Parfenov, A G Konoplyannikov, O N Boldyreva
Published 2016-02-01

Adherence to therapy of patients with inflammatory bowel diseases

by A I Parfenov, A V Kagramanova, A F Babayan, O V Knyazev
Published 2018-12-01

Biomarkers of inflammatory bowel disease activity

by N A Fadeeva, I A Korneeva, O V Knyazev, A I Parfenov
Published 2018-12-01

Clostridium difficile in ulcerative colitis; a retrospective study

by O. V. Knyazev, A. V. Kagramanova, M. E. Chernova, I. A. Koroleva, A. I. Parfenov
Published 2018-11-01

Clostridium difficile in inflammatory bowel disease

by O V Knyazev, A V Kagramanova, M E Chernova, I A Korneeva, A I Parfenov
Published 2018-11-01

O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov

by O V Knyazev, A V Kagramanova, I A Korneeva, K K Noskova, S V Belousov, A I Parfenov
Published 2019-04-01

Anemia in inflammatory bowel diseases: the approaches to its diagnosis, treatment and prevention

by I. V. Gubonina, O. B. Shchukina, N. I. Stuklov, T. V. Gaponova, D. I. Abdulganieva, O. V. Knyazev, N. S. Gubonina
Published 2020-01-01

Efficacy and tolerability of certolizumab pegol in Crohn's disease in clinical practice

by O V Knyazev, A V Kagramanova, A A Lishchinskaya, N G Samsonova, N V Orlova, V A Rogozina, A I Parfenov
Published 2018-06-01

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation

by O V Knyazev, T V Shkurko, A V Kagramanova, A A Lishchinskaya, M Yu Zvyaglova, I A Korneeva, A F Babayan, A I Parfenov
Published 2019-08-01

Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars

by O. V. Knyazev, M. Yu. Zvyaglova, A. V. Kagramanova, I. A. Li, E. A. Sabelnikova, A. A. Lishchinskaya, D. S. Kulakov, A. I. Parfenov
Published 2021-02-01

Stem Cell Therapy for Perianal Crohn’s Disease

by O V Knyazev, N A Fadeeva, A V Kagramanova, N I Belyakov, N V Orlova, A A Lishchinskaya, A G Konoplyannikov, A I Parfenov
Published 2018-03-01

Immunogenetic markers for ulcerative colitis in adult population of moscow region

by D S Stavtsev, T A Astrelina, M M Azova, O A Mayorova, V J Zinkin, L L Lebedeva, T V Pukhlikova, A A Chumak, O V Knyazev
Published 2014-12-01

Long-term infliximab therapy for ulcerative colitis in real clinical practice

by O V Knyazev, A I Parfenov, A V Kagramanova, I N Ruchkina, P L Shcherbakov, N K Shakhpazyan, K K Noskova, T I Ivkina, S G Khomeriki
Published 2016-08-01